Journal of Biomedicine and Biotechnology
Volume 2009 (2009), Article ID 501736, 3 pages
doi:10.1155/2009/501736
Research Article

No Incidence of BRAF Mutations in Salivary Gland Carcinomas—Implications for Anti-EGFR Therapies

Regine Dahse,1 Katrin Kromeyer-Hauschild,2 Alexander Berndt,3 and Hartwig Kosmehl1

1Institute of Pathology, HELIOS Klinikum Erfurt, Nordhauser Str. 74, 99089 Erfurt, Germany
2Institute of Human Genetics and Anthropology, Friedrich Schiller University of Jena, Kollegiengasse 10, 07740 Jena, Germany
3Institute of Pathology, Friedrich Schiller University of Jena, Ziegelmühlenweg, 07740 Jena, Germany

Received 7 April 2009; Accepted 7 May 2009

Academic Editor: Fernando Schmitt

Copyright © 2009 Regine Dahse et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Milano, F. Longo, M. Basile, R. V. Iaffaioli, and F. Caponigro, “Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy,” Oral Oncology, vol. 43, no. 8, pp. 729–734, 2007. View at Publisher · View at Google Scholar · View at PubMed
  2. R. Dahse, O. Driemel, S. Schwarz, et al., “Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas,” British Journal of Cancer, vol. 100, no. 4, pp. 623–625, 2009. View at Publisher · View at Google Scholar · View at PubMed
  3. R. Dahse, O. Driemel, S. Schwarz, K. Kromeyer-Hauschild, A. Berndt, and H. Kosmehl, “KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas,” Oral Oncology. In press. View at Publisher · View at Google Scholar · View at PubMed
  4. H. Davies, G. R. Bignell, C. Cox, et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002. View at Publisher · View at Google Scholar · View at PubMed
  5. F. Di Nicolantonio, M. Martini, F. Molinari, et al., “Wildtype BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5705–5712, 2008.
  6. L. Barnes, W. Eveson, P. Reichart, and W. Sidransky, “Pathology and genetics of head and neck tumours,” in World Health Organization Classification of Tumours, pp. 210–242, IARC Press, Lyon, France, 2005.
  7. L. D. Locati, P. Bossi, F. Perrone, et al., “Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study,” Oral Oncology. In press. View at Publisher · View at Google Scholar · View at PubMed
  8. B. S. Glisson, G. Blumenschein, M. Francisco, J. Erasmus, R. Zinner, and M. Kies, “Phase II trial of gefitinib in patients with incurable salivary gland cancer,” Journal of Clinical Oncology, vol. 23, no. 16S, p. 5532, 2005.
  9. M. Agulnik, E. W. E. Cohen, R. B. Cohen, et al., “Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non-adenoid cystic carcinoma malignant tumors of the salivary glands,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3978–3984, 2007. View at Publisher · View at Google Scholar · View at PubMed
  10. M. Jhawer, S. Goel, A. J. Wilson, et al., “PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab,” Cancer Research, vol. 68, no. 6, pp. 1953–1961, 2008. View at Publisher · View at Google Scholar · View at PubMed
  11. A. Sartore-Bianchi, M. Martini, F. Molinari, et al., “PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies,” Cancer Research, vol. 69, no. 5, pp. 1851–1857, 2009. View at Publisher · View at Google Scholar · View at PubMed
  12. G. Sarkar, J. Cassady, C. D. K. Bottema, and S. S. Sommer, “Characterization of polymerase chain reaction amplification of specific alleles,” Analytical Biochemistry, vol. 186, no. 1, pp. 64–68, 1990.
  13. C. R. Newton, A. Graham, L. E. Heptinstall, et al., “Analysis of any point mutation in DNA. The amplification refractory mutation system [ARMS],” Nucleic Acids Research, vol. 17, pp. 2503–2516, 1989.